Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources

Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources

PURPOSEPrior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Diana del Cisne Pineda, Gabriel Berlingieri Polho, Yumi Ricucci Shinkado, Gustavo Alves Contado, Nathalia de Souza Crusoe, Vivian Naomi Horita, Joao Carlos Resende, Jamile Almeida Silva, Guilherme Fialho de Freitas, David Queiroz Muniz, Caio V. Suartz, Leopoldo Alves Ribeiro-Filho, Paulo M. Hoff, José Mauricio Mota
Format: Article
Language:English
Published: American Society of Clinical Oncology 2025-01-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO-24-00464
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://ascopubs.org/doi/10.1200/GO-24-00464

Similar Items